Summary: Heterozygous familial hypercholesterolemia is a common genetic disorder that leads to premature coronary artery disease. Despite aggressive lipid-lowering therapy, many patients with heterozygous familial hypercholesterolemia fail to achieve optimal low-density lipoprotein cholesterol (LDL-C) goals. We evaluated mipomersen, an apolipoprotein B synthesis inhibitor, to further lower LDL-C in patients with heterozygous familial hypercholesterolemia with coronary artery disease who were already on maximally tolerated lipid-lowering therapy and had LDL-C >2.6 mmol/L (100 mg/dL). The phase 2, double-blind, placebo-controlled trial randomized 124 patients (41 placebo, 83 mipomersen) to weekly subcutaneous mipomersen 200 mg or placebo (2:1) for 26 weeks. The primary end point was percent change in LDL-C from baseline at week 28. Safety assessments included adverse events, laboratory tests, and MRI assessment of hepatic fat. Mean LDL-C decreased 28.0% with mipomersen compared with a 5.2% increase with placebo (P<0.001), and 45.1%
Summary: Vascular complications associated with type 2 diabetes mellitus are a widespread clinical problem. The mechanism behind these complications is far from understood, and specific treatment is lacking. Endothelial dysfunction with reduced bioavailability of nitric oxide has been suggested to be of importance for development of atherosclerosis and diabetic vascular complications. Emerging evidence suggests that increased activity and the expression of arginase via the metabolism of L-arginine, which is a substrate for both arginase and nitric oxide synthase, may result in reduced levels of arginine available for nitric oxide production and hence endothelial dysfunction. In the current study, we demonstrate that patients with coronary artery disease with and without diabetes mellitus have impaired endothelial function in comparison with age-matched control subjects. Furthermore, we show that inhibition of arginase activity in the forearm of patients with diabetes mellitus and coronary artery disease markedly improves endothelial function. The improvement in endothelial function is more pronounced in patients with coronary artery disease and diabetes mellitus than in those with coronary artery disease alone. The beneficial effect of arginase inhibition is completely dependent on the increased bioavailability of nitric oxide. These novel observations suggest that arginase activity is a key factor for endothelial dysfunction in patients with coronary artery disease, in particular, among those with diabetes mellitus, by regulating the bioavailability of nitric oxide. Our findings suggest that arginase inhibition could be an effective pharmacological intervention to improve the vascular function in these patients.
Conclusions: Arginase inhibition markedly improves endothelial function in patients with CAD and type 2 diabetes mellitus suggesting that increased arginase activity is a key factor in the development of endothelial dysfunction. 1 
Randomized Comparison of Sevoflurane Versus Propofol to Reduce Perioperative Myocardial Ischemia in Patients Undergoing Noncardiac Surgery
Summary: On the basis of promising evidence in patients undergoing on-pump coronary artery bypass graft surgery, the American College of Cardiology/American Heart Association guidelines recommend the use of volatile anesthetics as beneficial in hemodynamically stable patients at cardiovascular risk undergoing noncardiac surgery (class IIa recommendation). In the present randomized, controlled trial, anesthesia maintenance with sevoflurane compared with propofol did not reduce the incidence of perioperative myocardial ischemia in patients with coronary artery disease or at risk for it undergoing major noncardiac surgery. In addition, the data did not suggest any effect of sevoflurane on postoperative N-terminal prohormone of brain natriuretic peptide release or on major adverse cardiac events at 12 months. These results are in agreement with observational data and data generated in a small randomized trial. This growing evidence questions the recommendation to preferentially use volatile anesthetics in noncardiac surgical patients at cardiac risk.
Conclusions: Compared with propofol, sevoflurane did not reduce the incidence of myocardial ischemia in high-risk patients undergoing major noncardiac surgery. The sevoflurane and propofol groups did not differ in postoperative NT-proBNP release, major adverse cardiac events at 1 year, or delirium. 4 .9% achieved LDL-C <2.6 mmol/L (100 mg/ dL), respectively. Mipomersen significantly (P<0.001) reduced apolipoprotein B (−26.3%) and lipoprotein(a) (−21.1%) compared with placebo. More frequent and severe injection site reactions occurred with mipomersen, and 5 mipomersen-treated patients (6%) had 2 consecutive alanine aminotransferase levels ≥3 times the upper limit of normal at least 7 days apart; none were associated with significant bilirubin increases. Hepatic fat content increased a median of 4.9% with mipomersen versus 0.4% with placebo (P<0.001). The clinical implications of such increases in hepatic fat and transaminase elevations are unclear and must be elucidated in longer-term studies. We conclude that mipomersen is effective to further reduce apolipoprotein B-containing lipoproteins, including LDL and lipoprotein(a), in patients with heterozygous familial hypercholesterolemia with coronary artery disease on statins and other lipid-lowering therapy.
Conclusions:
Mipomersen is an effective therapy to further reduce apolipoprotein B-containing lipoproteins, including LDL and lipoprotein(a), in HeFH patients with coronary artery disease on statins and other lipid-lowering therapy. The significance of hepatic fat and transaminase increases remains uncertain at this time. 3 Relationships of Coronary Heart Disease With 27-Hydroxycholesterol, Low-Density Lipoprotein Cholesterol, and Menopausal Hormone Therapy Summary: The study examined the potential roles of high blood cholesterol and the cholesterol metabolite 27-hydroxycholesterol (an endogenous selective estrogen receptor antagonist) in increasing the risk of coronary heart disease caused by menopausal hormone therapy. The findings indicate that higher levels of low-density lipoprotein cholesterol, but not 27-hydroxycholesterol, were related to risk of coronary heart disease and that low-density lipoprotein cholesterol, but not 27-hydroxycholesterol, further increased the risk of coronary heart disease in women exposed to menopausal hormone therapy. The risk of coronary heart disease resulting from menopausal hormone therapy begins to increase at a low-density lipoprotein cholesterol level of ≈3.36 mmol/L (130 mg/dL). Screening women for low-density lipoprotein cholesterol levels could be helpful in making a decision about whether to recommend menopausal hormone therapy.
Conclusions: This study found that 27OHC does not independently increase the risk of CHD, does not modify the increased risk of CHD resulting from MHT, and does not mediate the interaction of LDLC with MHT. Measuring blood lipids may aid in counseling individual women about initiating MHT and cardiovascular risk mitigation. 4 Improvement in Coronary Blood Flow Velocity With Acute Biventricular Pacing Is Predominantly Due to an Increase in a Diastolic BackwardTravelling Decompression (Suction) Wave Summary: Biventricular pacing is known to improve cardiac contractility. This study shows that, equally, it improves cardiac relaxation and the resultant suction effect from the distal circulation that enhances coronary flow velocity. Both ventricular resynchronization and better-timed filling (atrioventricular optimization) have this effect. Pressure and flow velocity changes that occur in the coronary artery may originate proximally (traveling forward from the aorta) or distally (traveling backward from the microcirculation). Wave intensity analysis is a tool used to identify the origins of any changes, even when they are occurring simultaneously. In systole, myocardial contraction creates a forward compression wave but also an opposing backward compression wave. In contrast, in diastole, myocardial relaxation causes a backward decompression (suction) wave that is not opposed by such a matching forward-traveling wave (because the aortic valve closes). The ability of myocardial relaxation to suck blood into the coronary tree appears to be the predominant drive for coronary perfusion, and this drive can be quantified in the form of the backward-traveling decompression wave. Biventricular pacing increases this wave by enhancing myocardial relaxation, as observed in this study. Increases in ventricular pressure responses, brought about by biventricular pacing or optimization of atrioventricular delay, correspond with increases in coronary flow velocity.
Conclusions: When biventricular pacing improves LV contraction and relaxation, it increases coronary blood flow velocity, predominantly by increasing the dominant diastolic backward decompression (suction) wave. 5 
Coronary Microvascular Dysfunction Induced by Primary Hyperparathyroidism is Restored After Parathyroidectomy
Summary: Chronic elevations of parathyroid hormone (PTH) caused by primary (PHPT) or secondary hyperparathyroidism have long been associated with higher morbidity and all-cause and cardiovascular mortality. Multiple lines of evidence from experimental and clinical studies suggest that PTH could be causally involved in the pathophysiology of cardiovascular disease. Along with the shift in the clinical presentation of patient with PTH disorders toward an early and asymptomatic phase, as a result of improved diagnosis, current studies need to elucidate the frequency and clinical significance of subtle cardiovascular abnormalities associated with PTH alterations, trying to define their exact pathophysiological role and their reversibility. The present study aimed to evaluate the influence of PTH on coronary microvascular function, assessed by coronary flow reserve by transthoracic Doppler echocardiography, in healthy subjects and in patients with asymptomatic PHPT without evidence for epicardial coronary artery disease. Interestingly, asymptomatic PHPT of recent onset is already associated with coronary microvascular dysfunction, which is completely restored after short-term successful parathyroidectomy. Indeed, PTH per se is a determinant of coronary flow reserve independently of established cardiovascular risk factors and of other parameters of mineral metabolism. Our findings suggest a novel role of PTH in the pathophysiology of cardiovascular disease and a noninvasive, simple, and objective diagnostic tool for the assessment and follow-up of coronary microvascular function. Our data may improve the management and treatment of PHPT in its asymptomatic initial phase and may explain why PHPT is associated with increased cardiovascular mortality and risk, although molecular mechanisms involved need to be further investigated.
Conclusions: PHPT patients have coronary microvascular dysfunction that is completely restored after parathyroidectomy. PTH independently correlates with the coronary microvascular impairment, suggesting a crucial role of the hormone in explaining the increased cardiovascular risk in PHPT. Summary: The majority of acute coronary syndrome events are the result of sudden luminal thrombosis, with 55% to 60% caused by plaque rupture, 30% to 35% resulting from plaque erosion, and a small portion due to a calcified nodule. In the present analysis using 3-vessel intravascular ultrasound and virtual histology imaging and comprehensive follow-up data from Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT), we describe the frequency of incidentally detected calcified nodules and the angiographic appearance, intravascular ultrasound and virtual histology intravascular ultrasound features, and natural history of patients whose arteries contain ≥1 calcified nodules. The incidence of calcified nodule was 17% per artery and 30% per patient. Two or more calcified nodules were detected in 48 coronary arteries (3%) in 76 patients (12%). The calcified nodules were located <40 mm from the ostium of the coronary artery in 85% of left anterior descending arteries and 86% of left circumflex arteries, whereas calcified nodules within the right coronary arteries were evenly and more distally distributed, similar to other vulnerable plaque types. Patients with calcified nodules were significantly older and had more plaque volume, more thick-cap fibroatheroma, but fewer events at follow-up that could be attributed to their calcified nodules. Therefore, although a culprit calcified nodule has been reported by 1 pathology group to be a cause (albeit rarely) of coronary thrombosis, incidentally detected nonculprit calcified nodules appear to be more benign and do not often lead to thrombosis as suggested by the low event rate in the present study.
Conclusions: Calcified nodules in untreated nonculprit coronary segments in patients with acute coronary syndromes were more prevalent than previously recognized. Although their distribution mirrored the origin of most thrombotic events, calcified nodules caused fewer major adverse events during 3 years of follow-up. Summary: Coronary plaques progresses in a highly individual manner. Identification of early stages of high-risk plaque may enable development of preemptive strategies to alter the natural history of high-risk plaque and avert adverse cardiac events. The purposes of the PREDICTION Study were to determine the role of local vascular characteristics on coronary plaque progression in humans and to relate plaque changes to clinical events. Five hundred six patients with an acute coronary syndrome treated with a percutaneous coronary intervention were enrolled. Vascular profiling using coronary angiography and intravascular ultrasound was used to reconstruct the artery and calculate endothelial shear stress and plaque/remodeling characteristics in vivo. Each reconstructed artery was divided into sequential 3-mm segments for serial analysis. Three-vessel vascular profiling was performed at baseline and in a subset of 374 patients 6 to 10 months later to assess plaque natural history. Clinical follow-up was performed at 1 year. Symptomatic clinical events were infrequent. Increase in plaque area at follow-up was predicted by baseline large plaque burden; decrease in lumen area was independently predicted by baseline large plaque burden and low endothelial shear stress. Large plaque size and low endothelial shear stress independently predicted increased plaque burden and worsening of luminal obstructions treated with a percutaneous coronary intervention at follow-up. Large plaque burden and low local endothelial shear stress provide independent and additive prediction to identify plaques that develop progressive enlargement and lumen narrowing. These observations may justify prospective, randomized trials to identify early stages of high-risk plaque and investigate the value of local preemptive interventions.
Conclusions: Large plaque burden and low local endothelial shear stress provide independent and additive prediction to identify plaques that develop progressive enlargement and lumen narrowing. Summary: Multiple cardiac disorders other than acute myocardial infarction such as tachyarrhythmia, heart failure, and myocarditis have been reported as potential causes of elevation in conventional troponins in the absence of coronary obstruction. Although the introduction of high-sensitivity cardiac troponin (hs-cTn) assays has facilitated the earlier diagnosis and treatment of acute myocardial infarction, many clinicians are now struggling with interpreting (borderline) hs-cTn values and drawing appropriate clinical conclusions. In this study, we evaluated 887 unselected patients presenting to the emergency department with symptoms suggestive of acute myocardial infarction. The discriminatory power of 3 novel hs-cTn assays in the distinction of patients with acute myocardial infarction and those with cardiac but noncoronary disease was scrutinized. Our main finding was that algorithms using ST-elevation, presentation values, and changes of hs-cTn values in the first hour accurately separated patients with acute myocardial infarction and cardiac but noncoronary disease. This finding was consistent with all 3 hs-cTn assays and was validated in an independent cohort. The decision to perform further invasive diagnostic procedures such as coronary angiography will certainly remain based on all clinical information available. However, measurement of hs-cTn and its absolute change in the first hour seems to be a valuable objective tool for physicians to evaluate the indication for early coronary angiography as shown by decision curve analysis.
Conclusions:
The combined use of hs-cTn at presentation and its early absolute change excellently discriminates between patients with AMI and those with cardiac noncoronary artery disease. 9 Sustained Ventricular Tachycardia and Ventricular Fibrillation Complicating Non-STSegment-Elevation Acute Coronary Syndromes Summary: Ventricular arrhythmias are a well-recognized and potentially lethal complication of acute coronary syndromes (ACS), affecting ≈1 in 20 patients with ST-segment-elevation myocardial infarction. At present, the management of sustained ventricular tachycardia/ventricular fibrillation in the setting of ACS includes β-blockade and correction of the underlying ischemia, primarily by revascularization. The objective of our analysis was to identify the frequency and timing of sustained ventricular tachycardia/ventricular fibrillation in non-ST-segment-elevation (NSTE) ACS patients enrolled in the Early Glycoprotein IIb/IIIa Inhibition in NSTE ACS (EARLY ACS) trial, a contemporary NSTE ACS population. Our study had 3 main findings. First, in a contemporary, high-risk NSTE ACS population, the frequency of sustained ventricular tachycardia/ ventricular fibrillation was lower than previously reported in ACS populations. Second, although infrequent, these events did not occur predominantly within 48 hours of presentation/enrollment. Finally, both early (≤48 hours) and late (>48 hours) ventricular tachycardia/ ventricular fibrillation events were associated with a markedly increased risk of death after discharge, even after adjustment for revascularization and left ventricular function. These data suggest that patients with NSTE ACS require monitoring beyond 48 hours and highlight the importance of investigating the efficacy of interventions such as the wearable defibrillator or an implantable cardioverterdefibrillator in preventing arrhythmic death in patients with early sustained ventricular tachycardia/ventricular fibrillation.
Conclusions: Sustained VT/VF is infrequent after NSTE ACS but is as likely to occur after 48 hours as within the first 48 hours. The marked increase in all-cause death among NSTE ACS patients with both early and late sustained VT/VF raises important considerations for aggressive monitoring beyond 48 hours and interventions to prevent arrhythmic death in these patients. 10 
Prevalence of Kawasaki Disease in Young Adults With Suspected Myocardial Ischemia
Summary: Kawasaki disease (KD) is an acute, self-limited vasculitis of unknown origin that occurs most commonly in young children. Diagnosis depends on recognition of the clinical syndrome because no diagnostic test exists. Thus, the prevalence of individuals with missed KD is unknown. Up to 25% of patients with untreated KD and 5% of those treated with intravenous immunoglobulin will develop coronary artery aneurysms. Persistent aneurysms may remain silent until later in life when myocardial ischemia can occur. The impact of coronary aneurysms and coronary artery damage caused by KD and their prevalence among young adults presenting with symptoms of cardiac ischemia have not previously been studied. This study systematically evaluated a population of young adults undergoing coronary angiography at 4 hospitals in San Diego, CA, to estimate the prevalence of antecedent KD as a potential cause. We found that ≈5% of young adults who undergo coronary angiography to evaluate symptoms for myocardial ischemia may have coronary artery aneurysms with KD as the underlying cause. Thus, coronary sequelae of KD are responsible for a small but important percentage of young adults who present with myocardial ischemia. As more children with a history of KD reach adulthood, adult cardiologists are likely to see increasing numbers of patients with acute and subacute presentations of coronary sequelae of KD. Cardiologists should be aware of this special subset of patients who may benefit from medical and invasive management strategies that differ from those used to treat atherosclerotic coronary artery disease.
Conclusions: Coronary sequelae of KD are present in 5% of young adults evaluated by angiography for myocardial ischemia. Cardiologists should be aware of this special subset of patients who may benefit from medical and invasive management strategies that differ from the strategies used to treat atherosclerotic coronary artery disease. to determine race-related differences in bleeding and outcomes. We found that among patients with ST-segment-elevation myocardial infarction receiving fibrinolysis, the bleeding rates were higher for blacks (n=2283) than whites (n=42 243; 10.9% versus 10.3%; adjusted odds ratio, 1.21; 95% confidence interval, 1.02-1.43). Similarly, in patients receiving primary percutaneous coronary intervention, the bleeding rates were higher in blacks (n=2826) than whites (n=46 332; 10.3% versus 7.8%; adjusted odds ratio, 1.33; 95% confidence interval, 1.13-1.56). Bleeding was associated with a higher risk of death in both ethnic groups. However, there was no overall racial difference in in-hospital mortality among those with bleeding or without bleeding treated with either fibrinolysis or primary percutaneous coronary intervention. We concluded that race-related differences existed in bleeding risk among patients with ST-segment-elevation myocardial infarction receiving reperfusion therapy that portend poor prognosis. Thus, the efficacy and safety of many new drugs or treatment strategies for any disease observed in clinical trials that enroll predominantly white patients may not be similar in other ethnic groups that are underrepresented in these trials.
Conclusions: Blacks with ST-segment-elevation myocardial infarction treated with either fibrinolysis or primary percutaneous coronary intervention had a higher risk of bleeding events than their white counterparts. Bleeding was associated with a similar increased risk of death in both ethnic groups treated by either reperfusion strategy. 12 
Systemic and Vascular Oxidation Limits the Efficacy of Oral Tetrahydrobiopterin Treatment in Patients With Coronary Artery Disease
Summary: Tetrahydrobiopterin (BH4) is an essential cofactor for endothelial nitric oxide synthase in the vascular endothelium. Under conditions of BH4 deficiency such as the increased oxidative stress associated with atherosclerosis, endothelial nitric oxide synthase can become uncoupled, leading to the production of reactive oxygen species rather than nitric oxide, thus exacerbating oxidative stress. Accordingly, pharmacological strategies to increase BH4 levels have been proposed as therapeutic options in vascular disease states. Short-term intra-arterial infusions of BH4 have been shown to improve endothelial function; however, the effect of a long-term oral strategy in patients with coronary artery disease is unknown. In this clinical trial, we have tested the hypothesis that long-term oral BH4 treatment can increase BH4 bioavailability and improve vascular function in patients with coronary artery disease compared with placebo. Our trial results, supported by mechanistic ex vivo experiments using human blood and vascular tissue, demonstrate that exogenous BH4 is rapidly oxidized to dihydrobiopterin, which lacks endothelial nitric oxide synthase cofactor activity, and may act as a competitive inhibitor of BH4. Thus, although BH4 levels are elevated by treatment, the corresponding elevation of dihydrobiopterin levels results in no net effect of treatment on vascular redox status and hence no effect on vascular function. Therefore, future studies should address alternative therapies to target BH4-mediated vascular function or should examine strategies to ameliorate the oxidation of exogenous BH4.
Conclusions: Oral BH4 treatment augments total biopterin levels in patients with established coronary artery disease but has no net effect on vascular redox state or endothelial function owing to systemic and vascular oxidation of BH4. Alternative strategies are required to target BH4-dependent endothelial function in established vascular disease states. Conclusions: The use of a PPI was independently associated with a higher rate of cardiovascular events in patients with acute coronary syndrome receiving clopidogrel. However, a similar association was observed between cardiovascular events and PPI use during ticagrelor treatment and with other non-PPI gastrointestinal treatment. Therefore, in the PLATO trial, the association between PPI use and adverse events may be due to confounding, with PPI use more of a marker for, than a cause of, higher rates of cardiovascular events.
14 Phospholipase A2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes Summary: Secretory phospholipase A2 (sPLA2) and lipoproteinassociated phospholipase A2 (Lp-PLA2) are enzyme biomarkers of increased cardiovascular risk and targets of emerging therapeutic agents. This study demonstrates that sPLA2 mass independently predicts death during a 16-week period after acute coronary syndrome (ACS). High-dose atorvastatin significantly reduces sPLA2 and Lp-PLA2 mass and activity after ACS and mitigates the risk of death associated with sPLA2 mass. Atorvastatin may exert antiinflammatory effects on phospholipases that contribute to its therapeutic benefit after ACS. These findings, derived from a large, randomized, placebo-controlled study and measuring sPLA2 and Lp-PLA2 mass and activity for the first time in the same data set, provide an important roadmap for interpreting future studies on sPLA2 and Lp-PLA2 inhibitors. The observations in this analysis are timely because novel inhibitors of Lp-PLA2 and sPLA2 are being evaluated for clinical efficacy in large, prospective, randomized trials involving patients with recent ACS (SOLID, VISTA-16). These inhibitors may reduce the mass and/or activity of these phospholipases. Since the completion of the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) and Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT) trials, intensive statin treatment has become the standard of care after ACS. Therefore, future data sets will not provide the opportunity of the placebo-controlled MIRACL trial to assess both the natural history and prognostic value of phospholipase A2 biomarkers after ACS in the placebo arm and the modulation of these patterns by intensive statin treatment.
Conclusions: sPLA2 mass independently predicts death during a 16-week period after acute coronary syndrome. High-dose atorvastatin significantly reduces sPLA2 and Lp-PLA2 mass and activity after acute coronary syndrome and mitigates the risk of death associated with sPLA2 mass. Atorvastatin may exert anti-inflammatory effects on phospholipases that contribute to its therapeutic benefit after acute coronary syndrome. We found that patients who experienced an MI during follow-up had a higher risk of cardiovascular death than patients without an MI. Importantly, this higher risk was present across all subtypes of MI, including type 1 (spontaneous), type 4a (peri-percutaneous coronary intervention), and type 4b (stent thrombosis). Our findings demonstrate the applicability of the ESC/ACCF/AHA/WHF Universal MI Classification System and underscore the clinical relevance of MI and the need for better therapies aimed at attenuating the risk of recurrent MI after acute coronary syndromes.
Conclusions: MI is associated with a significantly increased risk of cardiovascular death, with a consistent relationship across all types as defined by the universal classification system. These findings underscore the clinical relevance of these events and the importance of therapies aimed at preventing MI. Summary: Although procedure-related myocardial infarction (MI) has been linked to adverse outcomes, the independent prognostic significance has been a topic for debate. This is in contrast to a spontaneous MI, which is clearly associated with adverse outcomes. We evaluated long-term cardiovascular mortality after both types of MI in the FRISC II, ICTUS, and RITA-3 (FIR) pooled data set of patients with non-ST-elevation acute coronary syndrome randomized to either a routine invasive or a selective invasive treatment strategy and 5-year follow-up of all patients. After adjustments for established risk factors for adverse long-term outcomes, no increased 5-year cardiovascular mortality was observed after the occurrence of a procedure-related MI within 6 months after randomization (hazard ratio 0.66; 95% confidence interval, 0.
35-1.25; P=0.20).
In contrast, the occurrence of a spontaneous MI within 6 months after randomization was associated with a substantially increased cardiovascular mortality (adjusted hazard ratio 2.79; 95% confidence interval, 2.04-3.83; P<0.001). In conclusion, long-term follow-up of all patients with non-ST-elevation acute coronary syndrome randomized to routine versus selective invasive treatment in the FIR trials showed a substantial adverse prognostic impact of spontaneous MI but no association between events that fulfilled the criteria of procedure-related MI and 5-year cardiovascular mortality. Potential clinical implications or questions include the need to routinely measure serial cardiac biomarkers after revascularization, the interpretation or use of a procedure-related MI as an outcome in clinical trials, and the use of medical treatment to reduce these procedure-related MIs.
Conclusions: Five-year follow-up of patients with non-ST-elevation acute coronary syndrome from the 3 trials showed no association between a procedure-related MI and long-term cardiovascular mortality. In contrast, there was a substantial increase in long-term mortality after a spontaneous MI. 17 
Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients With Stable Coronary Disease
Summary: The benefit of angiotensin-converting enzyme inhibitors in low-risk patients with stable coronary artery disease without heart failure remains controversial, and current practice guidelines note that it is reasonable but not recommended to use angiotensinconverting enzyme inhibitors when cardiovascular risk factors are well controlled and revascularization has been performed. We now demonstrate that elevated levels of 3 novel biomarkers of cardiovascular stress, midregional proatrial natriuretic peptide, midregional proadrenomedullin, and C-terminal proendothelin-1, are associated with the subsequent risk of cardiovascular death and heart failure independently of clinical factors (adjusted hazard ratios per 1-SD increase of 1.97, 1.48, and 1.47, respectively; P≤0.002 for each biomarker). Furthermore, elevated levels of these biomarkers identified patients in whom therapy with an angiotensin-converting enzyme inhibitor resulted in a significant reduction in the risk of cardiovascular death or heart failure. Specifically, trandolapril significantly reduced the risk of cardiovascular death or heart failure in patients who had elevated levels of ≥2 biomarkers (hazard ratio, 0.53; 95% confidence interval, 0.36-0.80), whereas there was no benefit in patients with elevated levels of 0 or 1 biomarker (hazard ratio, 1.09; 95% confidence interval, 0.74-1.59; Pinteraction=0.012). Thus, in patients with stable coronary artery disease and preserved left ventricular ejection fraction, elevated levels of novel biomarkers of cardiovascular stress identify patients who are at higher risk of cardiovascular death and heart failure and may be useful to select patients who derive significant benefit from angiotensin-converting enzyme inhibitor therapy.
Conclusions:
In patients with stable coronary artery disease and preserved left ventricular ejection fraction, our results suggest that elevated levels of novel biomarkers of cardiovascular stress may help identify patients who are at higher risk of cardiovascular death and heart failure and may be useful to select patients who derive significant benefit from angiotensin-converting enzyme inhibitor therapy.
18
A Genetic Risk Score Is Associated With Incident Cardiovascular Disease and Coronary Artery Calcium: The Framingham Heart Study Summary: Several major discoveries in the genetics of cardiovascular disease (CVD) have been made in recent years. However, whether the addition of genetic information can improve current risk prediction models for CVD (eg, Framingham Risk Score) has not been well established. By using data from >3000 individuals from the Framingham Offspring Study, we demonstrate that a genetic risk score (GRS) composed of 13 genetic variants associated with myocardial infarction is associated with both incident coronary heart disease and CVD. Furthermore, we also show that the GRS is also associated with high coronary artery calcium, a subclinical marker of atherosclerosis. However, the addition of these genetic variants only led to modest improvements to risk assessment when added to the Framingham Risk Score. Our results suggest that the addition of available genetic information does not appreciably improve the assessment of future cardiovascular risk at present. As additional genetic variants are discovered, future iterations of a GRS will require further investigation.
Conclusions: A GRS composed of 13 SNPs associated with coronary disease is an independent predictor of cardiovascular events and of high CAC, modestly improves risk reclassification for incident CHD, and significantly improves discrimination for high CAC. The addition of recently discovered SNPs did not significantly improve the performance of this GRS.
19
Literature-Based Genetic Risk Scores for Coronary Heart Disease: The Cardiovascular Registry Maastricht (CAREMA) Prospective Cohort Study Summary: Genome-wide association studies (GWAS) have identified many single-nucleotide polymorphisms (SNPs) associated with coronary heart disease (CHD) or its risk factors. We tested the combined effect of those SNPs on incident CHD in a Dutch population. By summing the number of risk alleles, 3 genetic risk scores (GRS) were constructed (ie, a GRS based on all 179 SNPs, 1 based on 153 risk factor-associated SNPs and 1 based on 29 CHD-associated SNPs). These GRS were associated with future CHD but not independent from traditional risk factors (ie, age, sex, smoking, self-reported diabetes, parental history of myocardial infarction, blood lipids, blood pressure, and body mass index). Next, a weighted CHD GRS was constructed by summing the number of CHD-associated risk alleles multiplied by their effect sizes obtained from 2 GWAS. This GRS was associated with CHD independent of traditional risk factors and improved risk reclassification. Effect sizes are sometimes difficult to obtain; therefore, as an exploratory analysis, least absolute shrinkage and selection operator (LASSO) regression analysis was used to obtain weighting. Using this method on the 29 CHD SNPs, 3 SNPs and corresponding weights were selected for a GRS. This GRS performed equally to the weighted CHD GRS. When applied on all 179 SNPs, 14 SNPs and corresponding weights were selected for a GRS, which performed slightly better than the weighted CHD GRS. Thus, weighting is important, and, when weights are not available, LASSO regression might be used to construct a weighted GRS; however, this method must be tested in independent populations.
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Conclusions: A GRS composed of CHD SNPs improves risk prediction when adjusted for the effect sizes of the SNPs. Alternatively LASSO regression analysis may be used to achieve weighting; however, validation in independent populations is required. In this randomized, double-blind, dose-ranging phase 2b trial, elinogrel was found to have acceptable safety and tolerability compared with clopidogrel in the setting of nonurgent PCI.
Conclusions:
In patients undergoing nonurgent percutaneous coronary intervention and in comparison with clopidogrel, intravenous and oral elinogrel therapy did not significantly increase thrombolysis in myocardial infarction major or minor bleeding, although bleeding requiring medical attention was more common. The significance of these findings will need to be more definitively determined in future Phase 3 studies. 21 
Percutaneous Coronary Intervention Versus Optimal Medical Therapy in Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Summary: The optimal management of stable coronary artery disease is controversial. With evolving percutaneous coronary intervention strategies and novel medical therapies, the best evidence-based treatment strategy is unknown. In this meta-analysis of 7182 individuals, percutaneous coronary intervention, as compared with optimal medical therapy, did not reduce the risk of mortality, cardiovascular death, nonfatal myocardial infarction, or revascularization. Revascularization with percutaneous coronary intervention was associated with greater angina relief, compared with optimal medical therapy alone. It is unknown whether the above results hold true in the contemporary era of third generation drug-eluting stents and contemporary medical management. Larger studies with sufficient power are required to detect contemporary differences in treatment strategies.
Conclusions:
In this most rigorous and comprehensive analysis in patients with stable coronary artery disease, PCI, as compared with OMT, did not reduce the risk of mortality, cardiovascular death, nonfatal myocardial infarction, or revascularization. PCI, however, provided a greater angina relief compared with OMT alone, larger studies with sufficient power are required to prove this conclusively. 22 
Gene-Targeted Analysis of Copy Number Variants Identifies 3 Novel Associations With Coronary Heart Disease Traits
Summary: Copy number variants (CNVs) are a common form of genomic variation discovered in the past decade. CNVs are stretches of genomic DNA that have different numbers of copies among individuals and usually result from duplications or deletions of genomic regions. Although they may contain coding regions, most CNVs are thought to modulate their effects through noncoding regions, and they have previously been implicated in cardiovascular and other disease processes. Here, we describe a process of CNV identification using the cnvHap algorithm. Three of the novel CNVs identified were shown to significantly associate with CVD-associated phenotypes, and these associations were reproducible in other study cohorts examined. Although their role in disease is, as yet, not fully appreciated, CNVs, such as those described, may make certain individuals more prone to complex pathologies such as CVD. More generally, detection of CNVs, using methods such as that described in this study, may become an important part of genetic association studies.
Conclusions: This study supports the use of CNV detection algorithms such as cnvHap as potential tools for the identification of novel CNVs, some of which show significant association and replication with coronary heart disease risk phenotypes. However, the functional basis for these associations requires further substantiation.
23
Hospital Percutaneous Coronary Intervention Appropriateness and In-Hospital Procedural Outcomes: Insights From the NCDR Summary: Measuring PCI quality has traditionally focused on processes of care and postprocedural outcomes, such as in-hospital mortality, bleeding and vascular complication rates, and provision of guideline-recommended medications. PCI appropriateness is increasingly being incorporated into registries and quality improvement programs to measure the quality of patient selection for PCI, although the relationship to traditional PCI quality metrics is unknown. In a large national registry of PCI, we found no relationship between a hospital's proportion of inappropriate PCIs for nonacute indications and traditional performance measures of processes of care and postprocedural outcomes. The observed large hospital-level variation in the proportion of inappropriate PCIs suggests differences in the quality of patient selection that was unrelated to how well the procedure was performed and emphasizes the importance of both appropriateness and postprocedural outcomes to informing PCI quality. Systems to improve a hospital's selection of patients for PCI may include decision-making tools and interventions prior to patient arrival in the cardiac catheterization laboratory and will differ from systems to minimize procedural complications.
Conclusions:
In a national cohort of nonacute PCIs, a hospital's proportion of inappropriate PCIs was not associated with in-hospital mortality, bleeding, or medical therapy at discharge. This suggests PCI appropriateness measures aspects of hospital PCI quality that are independent of how well the procedure is performed. Therefore, PCI appropriateness and postprocedural outcomes are both important metrics to inform PCI quality. reduces significantly the costs as compared with an angiographicguided strategy. In small-vessel disease, an FFR-guided PCI strategy compared with an angiographic-guided strategy is associated with a significant reduction in (1) major adverse cardiovascular events; (2) combined death or nonfatal myocardial infarction (MI); (3) nonfatal MI alone; and (4) target vessel revascularization. This clinical benefit is achieved with a significant reduction in procedural costs.
Conclusions: FFR-guided PCI of small coronary arteries is safe and results in better clinical outcomes when compared with an angioguided PCI.
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Prevalence and the Long-term Coronary Risks of Patients With Kawasaki Disease in a General Population <40 Years: A National Database Study
Summary: Coronary arterial lesions develop in 5% to 15% of patients in the acute stage of Kawasaki disease (kDa), which is the most common form of pediatric systemic vasculitis. These coronary arterial lesions may persist and progress into stenoses, sometimes resulting in myocardial ischemia or infarction. In Taiwan, after the first reported case of kDa in 1976, the incidence of kDa was 69/100 000 children < 5 years: the only countries with a higher incidence were Japan (218/100 000) and Korea (113/100 000). To our knowledge, this study was the first to investigate the prevalence and long-term coronary risk in patients with kDa using a nationwide Taiwanese database (representing > 98% of the general population spanning 11 years). We found that the prevalence of kDa was 34.9/100 000 in those aged < 40 years, and the annual coronary risk was 2.4%. An AMI occurred in 19 patients (18 males and 1 female) at a median age 15.7 years. The chance of coronary intervention in kDa patients, although still low, was much higher than that in the general population. Patients with kDa, particularly males, carry long-term coronary risks from a young age.
Conclusions: This study estimated the overall prevalence of kDa (≈1/2940) in a population < 40 years. They, particularly the males, carry long-term coronary risks from a young age. Risk stratification for a timely coronary intervention and risk modification are mandatory. Summary: Coronary imaging with magnetic resonance has historically been challenging, but recent technical advantages may overcome prior limitations to reliable detection of coronary artery stenosis. This study evaluated whole-heart navigator-gated, ECG-triggered and free-breathing coronary magnetic resonance angiography acquired after intravenous infusion of gadolinium-based contrast successfully performed in 101 patients also undergoing traditional invasive x-ray angiography. Magnetic resonance angiography acquisition time averaged 7.0±1.8 minutes. For a cutoff of 50% luminal stenosis by quantitative coronary angiography, 3-dimensional magnetic resonance angiography performed well, with positive and negative predictive values averaging 87.0% and 95.7%, respectively. With contemporary techniques, coronary magnetic resonance angiography can be performed efficiently, and warrants greater consideration as a suitable noninvasive method to exclude obstructive coronary artery disease.
Conclusions: Whole-heart coronary MRA at 3.0T using a 32-channel cardiac coil allows high overall accuracy for detecting significant coronary artery disease with reduced imaging time. It has potential to be a robust and alternative technique for ruling out significant coronary artery disease. Summary: Coronary artery disease remains the most important cause of left ventricular dysfunction. Patients with ischemic cardiomyopathy are at high risk of sudden cardiac death. The implantable cardioverter-defibrillator is now a common therapy for primary prevention in these patients. However, this indication is based exclusively on a poor left ventricular ejection fraction. Chronic total coronary occlusion (CTO) has been reported to be present in as many as 30% of patients with ischemia and has an adverse impact in long-term survival. In the present VACTO (Impact of Chronic Total Coronary Occlusion) Primary Study, we included real-world patients who underwent implantable cardioverterdefibrillator implantation for primary prevention and assessed the prognostic value of prior angiographic evidence of at least 1 CTO on ventricular arrhythmias and their additive impact on mortality in such patients. At 2 years, the cumulative incidence of appropriate implantable cardioverter-defibrillator therapy was higher in the CTO group than in the non-CTO group (26% versus 9%, P=0.01).
The findings support that CTO is a strong independent predictive factor for the occurrence of ventricular arrhythmias (hazard ratio, 3.5; 95% CI, 1.5%-8.3%).
Conclusions:
In patients with ischemic heart disease receiving ICDs for primary prevention of SCD, CTO is an independent predictor for the occurrence of ventricular arrhythmias and has an adverse impact on long-term mortality.
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Dimensions of Socioeconomic Status and Clinical Outcome After Primary Percutaneous Coronary Intervention
Summary: There is a well-known association between low socioeconomic status (SES) and high incidence of and mortality from coronary heart disease. There also appear to be SES-related differences in care among ST-elevation myocardial infarction patients, but the exact role of SES in relation to post-ST-elevation myocardial infarction outcomes remains poorly understood. Even in a universal, tax-financed, healthcare system, low-SES ST-elevation myocardial infarction patients treated with primary percutaneous coronary intervention face a worse prognosis than high-SES patients. The poor outcome seems to be primarily explained by differences in baseline patient characteristics, rather than differences in acute treatment or long-term secondary medical prophylaxis. Employment status and income, but not education level, were associated with clinical outcomes.
Conclusions: Even in a tax-financed healthcare system, low-SES patients treated with primary percutaneous coronary intervention face a worse prognosis than high-SES patients. The poor outcome seems to be largely explained by differences in baseline patient characteristics. Employment status and income (but not education level) were associated with clinical outcomes.
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Care Summary: The aging heart is susceptible to structural and functional changes that increase the risk of heart failure, which continues to rise in our aging population. Although seminal advances have been made in our understanding of changes to the cardiomyocyte and extracellular matrix in aging as well as in disease, less has been made on global alterations of the coronary vasculature. Our study aimed to provide insights into age-associated changes in the coronary vasculature using high-resolution microcomputed tomography (micro-CT) imaging technology. This technology gives us the ability to evaluate the entire coronary circulation, which we are unable to do with conventional histomorphometric techniques. In this study, using an experimental Fischer rat model of aging, we demonstrated important changes in the epicardial and intramyocardial coronary vessels, at varying arterial luminal diameters, between young and aged Fischer rats using micro-CT imaging. Specifically, in the setting of a growing myocardium due to aging, we observed the increase in epicardial coronary vessel volume, whereas the intramyocardial coronary vessel volume was reduced. Hence, cardiac micro-CT technology represents a powerful imaging tool that provides a greater and more representative understanding of adaptive changes to the entire coronary circulation in aging and could also provide important insights into other pathological states as well.
Conclusions: This micro-CT imaging study reports the reduction in normalized intramyocardial vessel volume within the aged heart, in association with increased epicardial vessel volume, in the setting of increased LV fibrosis, and mild LV dysfunction. 33 Interplay of Coronary Artery Calcification and Traditional Risk Factors for the Prediction of All-Cause Mortality in Asymptomatic Individuals
Summary: Current guidelines recommend the use of coronary artery calcium (CAC) scoring for select intermediate-risk patients. In the present study, we followed 44 052 consecutive asymptomatic individuals for a median of 5 years. Subjects without risk factors (obtained from patients) but elevated CAC had a significantly higher event rate than individuals with multiple risk factors but no CAC. Conversely, the absence of CAC was associated with a favorable prognosis even among those with multiple risk factors. These findings suggest a potential benefit of CAC over traditional risk assessment to tailor primary prevention therapy. However, further studies based on prospectively collected and quantitative data on risk factors are needed to determine whether CAC in the absence of risk factors enable more effective treatment and reduce overall healthcare costs.
Conclusions: By highlighting that individuals without RFs but elevated CAC have a substantially higher event rates than those who have multiple RFs but no CAC, these findings challenge the exclusive use of traditional risk assessment algorithms for guiding the intensity of primary prevention therapies. 34 
Association of Early Repolarization and Sudden Cardiac Death During an Acute Coronary Event
Summary: Electrocardiographic early repolarization (ER) pattern has been previously associated with arrhythmic mortality and with an increased risk of ventricular fibrillation. In the present study, the investigators analyzed ER from 432 consecutive victims of sudden cardiac death because of acute coronary event and 532 survivors of such an event, in whom 12-lead ECGs recorded before and unrelated to the event could be evaluated. ER pattern was found to be independently associated with sudden cardiac death during an acute ischemic coronary event. This novel observation suggests that the presence of ER increases the vulnerability to fatal arrhythmia during acute myocardial ischemia and provides a plausible mechanistic link between this ECG pattern and higher arrhythmic mortality in middle-aged/ elderly subjects. It also gives some preliminary information on the question of how physicians should treat asymptomatic individuals with ER; primary prevention of the first ischemic event is crucial.
Conclusions: Higher prevalence of ER in a standard 12-lead ECG in victims of SCD than in survivors of an acute coronary event suggests that the presence of ER increases the vulnerability to fatal arrhythmia during acute myocardial ischemia and provides a plausible mechanistic link between this ECG pattern and higher arrhythmic mortality of middle-aged/elderly subjects. 35 
